key: cord-0990759-8e7tapme
authors: Sepulcri, Chiara; Dentone, Chiara; Mikulska, Malgorzata; Bruzzone, Bianca; Lai, Alessia; Fenoglio, Daniela; Bozzano, Federica; Bergna, Annalisa; Parodi, Alessia; Altosole, Tiziana; Delfino, Emanuele; Bartalucci, Giulia; Orsi, Andrea; Di Biagio, Antonio; Zehender, Gianguglielmo; Ballerini, Filippo; Bonora, Stefano; Sette, Alessandro; De Palma, Raffaele; Silvestri, Guido; De Maria, Andrea; Bassetti, Matteo
title: The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient – a case study
date: 2021-04-28
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab217
sha: ef887e21349e25c25bd0429d665bd1c59c6a49f4
doc_id: 990759
cord_uid: 8e7tapme

BACKGROUND: Immunocompromised patients show prolonged shedding of SARS-CoV-2 in nasopharyngeal swabs. We report a case of a prolonged persistence of viable SARS-CoV-2 associated with clinical relapses of COVID-19 in a patient with mantle-cell lymphoma who underwent treatment with R-BAC (rituximab, bendamustine, cytarabine) with consequent lymphopenia and hypogammaglobulinemia. METHODS: Nasopharyngeal swabs and blood samples were tested for SARS-CoV-2 by Real time-PCR (RT-PCR). On five positive nasopharyngeal swabs, we performed viral culture and next generation sequencing. We analysed the patients’ adaptive and innate immunity to characterize T and NK cell subsets. RESULTS: SARS-CoV-2 RT-PCR on nasopharyngeal swabs samples remained positive for 268 days. All five performed viral cultures were positive and genomic analysis confirmed a persistent infection with the same strain. Viremia resulted positive in three out of four COVID-19 clinical relapses and cleared each time after remdesivir treatment. T and NK cells dynamic was different in aviremic and viremic samples and no SARS-CoV-2 specific antibodies were detected throughout the disease course. CONCLUSIONS: In our patient, SARS-CoV-2 persisted with proven infectivity for over eight months. Viremia was associated with COVID-19 relapses and remdesivir treatment was effective in viremia clearance and symptoms remission, although it was unable to clear the virus from the upper respiratory airways. During the viremic phase, we observed a low frequency of terminal effector CD8+ T lymphocytes in peripheral blood that are probably recruited in inflammatory tissue for viral eradication. In addition we found a high level of NK cells repertoire perturbation with a relevant involvement during SARS-CoV-2 viremia.

Persistence of SARS-CoV-2 viral shedding and recurrence of positive SARS-CoV-2 nasopharyngeal swab after a negative sample and symptoms remission have been documented both in asymptomatic and symptomatic patients. 1 Nevertheless, viral infectivity cannot be determined with Real time-PCR (RT-PCR), which detects only viral RNA, and viral culture and genome sequencing to determine the infectivity and genomic asset of the virus cannot be routinely used in clinical practise, leading to uncertainty about definitions of re-infection, relapse, prolonged viral shedding and infectiousness. Studies assessing the infectivity of these isolates have documented that viral infectivity declines within ten days of infection, with a possible tail of another ten days, both in asymptomatic and symptomatic individuals. 2 In immunocompromised patients, prolonged viral shedding with proven viral infectivity is increasingly been reported [3] [4] [5] [6] [7] and in two cases it was associated with disease relapse. [3] [4] Adaptive and innate immunity play a vital role in viral clearance: during many acute infections, including SARS-CoV-2, the presence of CD8+ cytotoxic T cells capable of secreting an array of molecules such granzymes to eradicate virus from the host has been described. 8 At the same time, CD4+ helper T cells can assist cytotoxic T cells and enhance their ability to clear pathogens. However, persistent stimulation by the virus may induce T cell exhaustion as a state of T cells dysfunction, leading to loss of cytokine production and reduced function. 9 Our case represents the longest SARS-CoV-2 viral persistence with proven viral infectivity in an immunocompromised patient who experienced four clinically relevant COVID-19 relapses. Relapses were associated with positive viremia and responded to remdesivir treatment with viremia clearance and symptoms remission but with persistence of viable virus in the upper respiratory A c c e p t e d M a n u s c r i p t 7 airways. We observed a difference in T and NK cells distribution between aviremic and viremic phases.

RT-PCR on nasopharyngeal swabs was performed with Allplex 2019 nCOV Seegene -Three Target assay [sensitivity 98·2%, specificity 100%]. 10 Viral isolation and culture from nasopharyngeal swab samples was performed on VERO E6 cells ( Figure 1 ). We extracted RNA for confirmation of SARS-CoV-2 by RT-PCR and next generation sequencing. We obtained full genome sequences from the supernatant at different time points with Miseq Illumina (Illumina, Inc. San Diego) using 2x150 paired-end sequencing. We mapped and aligned the results to the reference genome obtained from Gisaid (https://www.gisaid.org/, accession ID: EPI_ISL_412973) 11 using Geneious software, v. 9.1.5 (http://www.geneious.com). 12 We used Nextclade and Pangolin systems (freely available at https://clades.nextstrain.org/ and https://pangolin.cog-uk.io/, respectively) 13,14 for strain classification.

SARS-CoV-2 IgG and IgM antibody testing was performed using Thermo Scientific TM COVID-19 Total Antibody ELISA test.

We assessed T cells and NK cells activity on one viremic (Day 84) and one aviremic (Day 146) blood samples by BD Fortessa X20 flow cytometer (BD Biosciences) with the BD FACSDiva software (version 8.0; BD Biosciences) and by Activation Induced Marker (AIM) assay, 15 a cytokineindependent approach using specific peptide megapools (MP), identified by bioinformatic approaches. 16 We used multidimensional data reduction analysis through t-dependent Stochastic Neighbor Embedding (t-SNE) analysis to examine CD8+ T cells' marker expression.

A c c e p t e d M a n u s c r i p t 8

The patient was aware of the conduct and dissemination of this case-study and provided verbal and written informed consent allowing the dissemination of this case-study. Unfortunately, the COVID-19-related emergency situation did not allow safe storage of the written consent.

The study was carried out in accordance with the principles of the Declaration of Helsinki and approved by the Ethic Committee of Liguria Region (Comitato Etico Regione Liguria) (N. CER Liguria 114/2020 -ID 10420).

On the 24 th of March 2020, during the SARS-CoV-2 initial wave in Italy, 17 a 70 year-old male was hospitalized in Genoa, Italy, for the sudden onset of fever, dry cough and respiratory distress. The Viremia clearance was observed all three times, always after remdesivir treatment (five, seven, and two days after the end of treatment, respectively). Table 1 . Patient sequences all belonged to clade 20B, corresponding to lineage B.1.1.

According to literature data, [18] [19] [20] [21] [22] [23] [24] [25] no mutations related to possible resistance to remdesivir were observed, also as minority variant when considering a cut off of 1% (Supplementary Table 1 

A c c e p t e d M a n u s c r i p t

We performed SARS-CoV-2 serology repeatedly throughout the disease course. In all cases, no specific antibodies (IgG or IgM) were detected in the patient's serum, even after infusion of convalescent plasma (which had an unspecified anti-SARS-CoV-2 titre). 

In this case study, we describe a case of 8-month persistence of SARS-CoV-2 RT-PCR positive nasopharyngeal swab in an immunosuppressed patient with non-Hodgkin lymphoma, with four clinically symptomatic relapses of COVID-19. During each relapse, the patient received a cycle of remdesivir that resulted in viremia clearance; however, viable virus remained detectable on A c c e p t e d M a n u s c r i p t 14 nasopharyngeal swabs. To the best our knowledge, this is the longest persistence of SARS-CoV-2 RT-PCR positive nasopharyngeal swab to be reported. Our report suggests that this persistence may be due to viable SARS-CoV-2 virus that can determine a well-defined innate and adaptive cellular immune response compatible with disappearance of viremia, whose presence correlated with symptomatic relapses, as previously reported. 26, 27 Remdesivir was effective in clearing blood viremia and was associated with clinical recovery every time it was administered but was unable to clear SARS-CoV-2 from upper airways as inferred by the persistence of viable virus on repeat nasopharyngeal swabs. A ten-days treatment course with remdesivir was performed on one occasion and was associated with viremia clearance and a prolonged (70 days) disease-free period. Subsequent treatment courses were five-day long based on data of non-inferiority of five-days courses against ten-days courses. 28 As other authors, we can speculate that longer courses of remdesivir might be beneficial in immunocompromised patients, 29, 30 however, at the time of writing, no definite evidence in this regard has been established, and five days were sufficient for viremia clearance and clinical improvement in our case. Furthermore, prolonged antiviral administration, as a prophylaxis of clinical relapse, is an unexplored yet interesting option.

Convalescent plasma therapy has proven efficacious in viremia clearance and resolution of COVID-19 symptoms in specific circumstances, such as in patients with B-cell depletion after anti-CD20 treatment. 31 In our case, a single treatment course was administered because of apparent lack of benefit, piling negative data from randomised trials 32, 33 Since the disease course of this immunosuppressed patient was characterized by persistent viral shedding with intermittent viremia, we set to study whether an adaptive and innate immune response could be characterized in the different viremic phases. Taken together, the analyses highlighted profound differences in both the regulatory and the effector arm of T cell adaptive immunity in viremic and aviremic samples with an activated cytotoxic phenotype displayed by acutephase SARS-CoV-2-specific T cells, as previously reported. 34, 35 During the viremic phase, we observed a high frequency of CD4+FoxP3+CD25+ T cells (T reg cells, tenfold higher than in the aviremic phase) and a reduced frequency of terminal effector CD8+ T lymphocytes (18% vs 68%) which is attributable to CD8+ T cells' ability to migrate into tissues affected by inflammation to control the virus. This finding is in line with the dual function performed by Treg during SARS-CoV-2 infection, since it may indicate that in patients with COVID-19 CD4+ Treg are generated/recruited in the attempt to counteract the overwhelming inflammatory response, but also that Treg expansion may hamper virus-specific effector responses.

Moreover, the analysis of exhaustion marker expression confirmed the different dynamic in viremic and aviremic sample. In fact, terminally differentiated memory cells were more present in the aviremic sample with respect to the viremic sample and consequently the frequency of CD8+ PD-1+ and CD8+EOMES+ cells decreased in the aviremic sample (CD8+PD-1+/CD8+ and CD8+EOMES+/CD8+ were 53% and 49% in the viremic sample, respectively, while CD8+PD-1+/CD8+ and CD8+EOMES+/CD8+ were 15.7% and 22.3% in the aviremic sample, respectively). These data seem to suggest the elimination of a brake on the immune response. The analysis of specific T cell response in aviremic sample confirms this hypothesis and a fraction of specific CD4+ and CD8+ T cells were described in the aviremic sample.

Furthermore, we observed a high level of NK cell repertoire perturbation with a relevant involvement of NKp44+ and NKG2D+ NK cells during SARS-CoV-2 viremia. A considerable degree of activation of NK cells was observed, with increased HLA-DR expression. This level of activation is A c c e p t e d M a n u s c r i p t 16 comparable to previous findings observed in people living with HIV with either detectable 36 and undetectable viremia due to suppressive antiretroviral therapy (ART) 37 or in elite controllers and long-term non-progressors. 38 A level of NK cell activation comparable to our case was also found in immunocompetent, symptomatic patients with COVID-19 pneumonia requiring oxygen supplementation at the time of admission as inpatients. 39 

The authors received no specific funding for this work.

None of the authors reported any conflict of interest relevant to the present work. M a n u s c r i p t 

SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. The Lancet Microbe

Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Evaluation of three commercial assays for SARS-CoV-2 molecular detection in upper respiratory tract samples

Clade and lineage nomenclature aids in genomic epidemiology studies of active hCoV-19 viruses

Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data

Targets of T Cell Responses to SARS-CoV-2

Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

The Immune Epitope Database and Analysis Resource Program 2003-2018: reflections and outlook

The Impacts of Antivirals on the Coronavirus Genome Structure and Subsequent Pathogenicity, Virus Fitness and Antiviral Design

Rational Design of the Remdesivir Binding Site in the RNAdependent RNA Polymerase of SARS-CoV-2: Implications for Potential Resistance

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases

Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19

Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action

Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses

SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study

Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir

Convalescent plasma therapy for B-celldepleted patients with protracted COVID-19. Blood

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients

Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation

Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation

Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity

Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study

Thanks to BC and his family, for enduring the hardest times with dignity and determination and for always trusting us.Thanks to Dr. Rosanna Vagge for her tireless job and for being always available.A special thanks to Dr. Justin Koh, who provided a fast and accurate English revision.

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t